Report Scope:
This report will provide a detailed overview of ovarian cancer, highlighting treatment guidelines with information on the current and potential global market for ovarian cancer and treatments and testing technologies with a detailed analysis of the competitive landscape, including new potential markets for novel products, diagnostics, and therapeutics development.
The report covers the regulatory environment, current and new technologies, ovarian cancer incidence, market projections and market share along with the latest trends and new developments, recent approvals, the research and development pipeline, and blockbuster drugs. It also covers global and regional markets for ovarian cancer diagnostics and therapies, providing reasons for variations in the growth of the industry across regions.
The report also analyzes the competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include AbbVie Inc, Astra Zeneca, Bristol-Myers Squibb Company, Celgene Corp., Clovis Oncology, Eli Lilly and Company, GlaxoSmithKline plc, Hikma Pharmaceuticals PLC, Janssen Pharmaceuticals, Inc., Merck & Company, Inc., Myriad Genetics Inc., Novartis AG, Pfizer, Inc., Quest Diagnostics Inc., Roche Holding AG and Tesaro, Inc.
Report Includes:
- 28 data tables and 9 additional tables
- A comprehensive analysis of the ophthalmic device market by reviewing recent advances in diagnostic, surgical, and implantation devices that can be used to treat prevalent eye conditions.
- Analyses of global market trends with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022.
- Breakdowns of the market by device, application, and region.
- Analysis of the recent advances in ophthalmic medical devices and their potential impact on the medical device industry.
- Evaluation of the market’s dynamics, specifically growth drivers, restraints, and opportunities.
- Company profiles of major players in the market, including AbbVie Inc., Bristol-Myers Squibb, Clovis Oncology, Inc., Eli Lilly and Company and Pfizer Inc.
Membership Price:
Contact us for membership pricing.
Table of Contents
1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Methodology
- Geographic Breakdown
- Analyst's Credentials
- Related Research Reports
2 Summary and Highlights
- Market Context for Ovarian Cancer Therapies and Diagnostics
3 Overview and Biology
- Overview
- Biology
- Metastasis
- Risk Factors
- Family History
- Genetic Mutation
- Lynch Syndrome
- Peutz-Jeghers Syndrome
- Age
- Previous Conditions
- Prevention
- Birth Control
- Childbearing Status
- Removal of the Ovaries and Fallopian Tubes
- Hysterectomy/Tubal Ligation
- Symptoms
- Gastrointestinal
- Abdominal
- Whole Body
- Diagnosis
- Overview
- Current Screening Practices
- Stages of Ovarian Cancer
- Stage I
- Stage II
- Stage III
- Stage IV
4 Market Dynamics and Technology Background
- Market Definition and Overview
- Market Drivers
- Increase in Healthcare Expenditures
- Continued Emphasis on R&D activities in Cancer and Treatment Technologies
- Promised Potential of Alternative Therapies
- Greater Understanding of the Genetic Base of lndividual Cancers
- Increasing incidences of Ovarian Cancer Worldwide
- Greater Use of Combination Therapies for Treatment
- Increasing Cancer Prevalence Rates and Aging Population
- Rising Awareness Among People with Cancer and Its Treatment
- Market Restraints
- Lack of Accurate Diagnosis of Ovarian Cancer
- The Launch of Generic Drugs
- Market Opportunities
- Rising Female Population in the Asia-Pacific Region
- Aging Demographics in Japan
- Technological Advancements in the Drug Sector
- Emergence of New Therapies for Disease Control
5 Market Breakdown by Diagnosis
- Overview
- Background
- Diagnostic Tests
- Pelvic Exam
- Laboratory Tests
- Recurrent Ovarian Epithelial Cancer
- Market Forecast
- New Developments
6 Ovarian Cancer Treatment
- Treatment Strategies for Ovarian Cancer
- Current Treatment Practices
- Surgery
- Chemotherapy
- Intraperitoneal Chemotherapy
- IV Chemotherapy
- Targeted Therapy
- Immunotherapy
- Radiation Therapy
- Palliative/Supportive Care
- Recurrent Ovarian Cancer
- Metastatic Ovarian Cancer
- Sensitive Cancer Treatment
- Resistant Cancer Treatment
- Recurrent Ovarian Epithelial Cancer
- Secondary Chemotherapy Drugs
- Surveillance After Treatment
- Novel Strategies for Prevention of Multidrug Resistance (MDR) in Cancer
7 Market Breakdown by Cancer Type
- Epithelial Ovarian Tumors
- Germ Cell Tumors
- Stromal Tumors
- Primary Peritoneal Cancer
- Stages of Ovarian Cancer
- Stage 1
- Stage 2
- Stage 3
- Stage 4
- Prognosis
8 Market Breakdown by Region
- Introduction
- North America
- U.S.
- Canada
- Europe
- Acquisitions and Collaborations
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- India
- China
- Japan
- Middle East & Africa
- Drivers
- Restraints
- Latin America
- Mexico
- Drivers
- Restraints
9 Pipeline Analysis
- Current Scenario
- New Product Developments
- VEGF Inhibitor
- PARP Inhibitors
- Promising Pipeline Molecules/Drugs in Development
- Atezolizumab
- Avelumab
- Lurbinectedin
- Veliparib
- Trametinib
- Fosbretabulin
- Mirvetuximab Soravtansine
- Most Promising Drug
- ONX-0801
- Recent Developments in the Ovarian Cancer Treatment
- Gene Therapy Inhibited Chemoresistant Tumor
- Synthetic Gene Circuit Development
- Novel Combination Therapy
- Birinapant
- CancerSEEK
10 Patent Analysis
- Overview
- Patent Expiration
11 Competitive Landscape and Key Developments
- Overview
- Major Players and Market Share
- Mergers and Acquisitions
- AbbVie and Stemcentrx
- Hikma Pharmaceuticals and EIMC United Pharmaceuticals
- Roche and Ignyta
12 Company Profiles
- ABBVIE INC.
- Business Overview
- Products and Services
- Imbruvica
- Venclexta
- Pipeline analysis
- Acquisitions
- Financials
- ASTRA ZENECA
- Business Overview
- Products and Services
- Tagrisso
- Lynparza
- Faslodex (Fulvestrant)
- Zoladex
- Ovarian Cancer Products
- Developments and Strategies
- Financials
- BRISTOL-MYERS SQUIBB
- Business Overview
- Products and Services
- Developments and Strategies
- Financials
- CELGENE CORP.
- Business Overview
- Products and Services
- Financials
- CLOVIS ONCOLOGY
- Business Overview
- Products and Services
- ELI LILLY AND COMPANY
- Business Overview
- Products and Services
- Gemzar
- Developments and Strategies
- Financials
- GLAXOSMITHKLINE PLC
- Business Overview
- Developments and Strategies
- Acquisition
- Financials
- HIKMA PHARMACEUTICALS PLC
- Business Overview
- Products and Services
- Developments and Strategies
- Acquisitions
- Financials
- JANSSEN PHARMACEUTICALS, INC.
- Business Overview
- Financials
- MERCK & CO., INC.
- Business Overview
- Financials
- MYRIAD GENETICS INC.
- Business Overview
- Products and Services
- Financials
- NOVARTIS AG
- Business Overview
- Products and Services
- Financials
- PFIZER INC.
- Company Overview
- Financials
- QUEST DIAGNOSTICS INC.
- Business Overview
- Products and Services
- Financials
- ROCHE HOLDING AG
- Business Overview
- Products and Services
- Acquisitions
- Financials
- TESARO, INC.
- Business Overview
- Products and Services
- Immuno-Oncology Platform
List of Tables
Summary Table A: Global Ovarian Cancer Therapeutic Market, by Cancer Type, Through 2022
Summary Table B: Global Ovarian Cancer Therapeutic Market, by Region, Through 2022
Table 1: Imaging Tests and Functionality
Table 2: Global Market for FDA Cleared/Approved Companion Diagnostic Devices for Cancer, by Category, Through 2022
Table 3: Global Ovarian Cancer Therapeutics Market, by Cancer Type, Through 2022
Table 4: Stage 1 and Substages of Ovarian Cancer
Table 5: Stage 2 and Substages of Ovarian Cancer
Table 6: Stage 3 and Substages of Ovarian Cancer
Table 7: Stage 4 and Substages of Ovarian Cancer
Table 8: Global Ovarian Cancer Therapeutics Market, by Region, Through 2022
Table 9: North America Ovarian Cancer Therapeutics Market, Through 2022
Table 10: Europe Ovarian Cancer Therapeutics Market, Through 2022
Table 11: Asia-Pacific Ovarian Cancer Therapeutics Market, Through 2022
Table 12: Middle East and Africa Ovarian Cancer Therapeutics Market, Through 2022
Table 13: Latin America Ovarian Cancer Therapeutics Market, Through 2022
Table 14: PARP Inhibitors
Table 15: Pipeline Drugs Summary, by Phase
Table 16: Global Sales at Risk from Patent Expiration, 2016-2022
Table 17: Drugs Scheduled to Lose Patent Protection, 2018
Table 18: Drugs Scheduled to Lose Patent Protection, 2019
Table 19: Oncology Segment Revenue of Major Players, 2016
Table 20: AbbVie Inc.'s Revenue, 2015-2016
Table 21: AstraZeneca's Revenue, 2015-2016
Table 22: Lynparza's Revenue, 2015-2016
Table 23: Bristol-Myers Squibb's Revenue, 2015-2016
Table 24: Celgene Corp.'s Revenue, 2015-2016
Table 25: Eli Lilly and Company's Revenue, 2015-2016
Table 26: GlaxoSmithKline's Revenue, 2015-2016
Table 27: Hikma Pharmaceutical's Revenue, 2015-2016
Table 28: J&J's Revenue, 2015-2016
Table 29: Merck & Co., Inc.'s Net Revenue, 2014-2016
Table 30: Myriad Genetics, Inc.'s Revenue, 2015-2016
Table 31: Novartis AG's Revenue, 2015-2016
Table 32: Pfizer, Inc.'s Net Revenue, 2014-2016
Table 33: Quest Diagnostics, Inc.'s Revenue, 2015-2016
Table 34: Roche Holding's Revenue, 2015-2016
Table 35: Avastin's Drug Revenue, 2015-2016
List of Figures
Summary Figure A: Global Ovarian Cancer Therapeutic Market, by Cancer Type, 2016-2022
Summary Figure B: Global Ovarian Cancer Therapeutic Market, by Region, 2016-2022
Figure 1: Woman's Reproductive System
Figure 2: Ovarian Cancer Symptoms
Figure 3: Pelvic Examination
Figure 4: Transvaginal Ultrasound (TVUS)
Figure 5: Pelvic Examination
Figure 6: Global Market for FDA Cleared/Approved Companion Diagnostic Devices for Cancer, 2016-2022
Figure 7: Global Market for FDA Cleared/Approved Companion Diagnostic Devices for Ovarian Cancer, 2016-2022
Figure 8: Epithelial Cancer Therapy Market, 2016-2022
Figure 9: Germ Cell Cancer Therapy Market, 2016-2022
Figure 10: Stromal Cancer Therapy Market, 2016-2022
Figure 11: Primary Peritoneal Cancer Therapy Market, 2016-2022
Figure 12: Stage 1 and Substages of Ovarian Cancer
Figure 13: Stage 2 and Substages of Ovarian Cancer
Figure 14: Stage 3 and Substages of Ovarian Cancer
Figure 15: Stage 4 and Substages of Ovarian Cancer
Figure 16: U.S. Ovarian Cancer Therapeutics Market, 2016-2022
Figure 17: Canada Ovarian Cancer Therapy Market, 2016-2022
Figure 18: Germany Ovarian Cancer Therapy Market, 2016-2022
Figure 19: U.K. Ovarian Cancer Therapy Market, 2016-2022
Figure 20: France Ovarian Cancer Therapy Market, 2016-2022
Figure 21: Italy Ovarian Cancer Therapy Market, 2016-2022
Figure 22: Spain Ovarian Cancer Therapy Market, 2016-2022
Figure 23: RoE Ovarian Cancer Therapy Market, 2016-2022
Figure 24: India Ovarian Cancer Therapy Market, 2016-2022
Figure 25: China Ovarian Cancer Therapy Market, 2016-2022
Figure 26: Japan Ovarian Cancer Therapy Market, 2016-2022
Figure 27: Middle East and Africa Ovarian Cancer Therapy Market, 2016-2022
Figure 28: Mexico Ovarian Cancer Therapy Market, 2016-2022
Figure 29: Lurbinectedin Chemical Structure
Figure 30: Velaparib Chemical Structure
Figure 31: Trametinib (Mekinist) Chemical Structure
Figure 32: Fosbretabulin Chemical Structure
Figure 33: Mirvetuximab Soravtansine Chemical Structure
Figure 34: ONX-0801 Chemical Structure
Figure 35: CancerSEEK Test
Figure 36: Global Sales at Risk from Patent Expiration, 2016-2022
Figure 37: Global Market Share of Major Players in OC Therapy Industry, 2016
Figure 38: Merck & Co., Inc.'s Revenue Share, by Business Segment, 2016
Figure 39: Merck & Co., Inc. Revenue Share, by Region, 2016
Figure 40: Pfizer, Inc.'s Revenue Share, by Region, 2016
Figure 41: Pfizer, Inc.'s Revenue Share, by Business Segment, 2016
Companies Mentioned
- Abbvie Inc.
- Astra Zeneca
- Bristol-Myers Squibb
- Celgene Corp.
- Clovis Oncology
- Eli Lilly And Company
- Glaxosmithkline PLC
- Hikma Pharmaceuticals PLC
- Janssen Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Myriad Genetics Inc.
- Novartis AG
- Pfizer Inc.
- Quest Diagnostics Inc.
- Roche Holding AG
- Tesaro, Inc.
